ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

BIOC Biocept Inc

0.4349
0.00 (0.00%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Biocept Inc NASDAQ:BIOC NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.4349 0.37 0.3799 0 01:00:00

Biocept Announces One-for-Thirty Reverse Stock Split

17/05/2023 1:00pm

Business Wire


Biocept (NASDAQ:BIOC)
Historical Stock Chart


From Jun 2022 to Jun 2024

Click Here for more Biocept Charts.

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that as a result of its 1-for-30 reverse stock split that became effective at 4:05 p.m. Eastern Time on May 16, 2023, its common stock will begin trading on a split-adjusted basis with the open of the market today, May 17, 2023. Biocept’s common stock will continue to trade under the existing trading symbol “BIOC.”

As a result of the reverse stock split, each 30 pre-split shares of common stock outstanding were automatically combined and converted into one issued and outstanding share of common stock. No fractional shares of common stock were issued to any stockholders in connection with the reverse stock split. Holders of record will receive a cash payment in lieu of fractional shares.

Stockholders of record will receive information regarding their share ownership following the reverse stock split from the Company’s transfer agent, Continental Stock Transfer & Trust. Continental Stock Transfer & Trust can be reached at (800) 509-5586 or (212) 509-4000 or by email at cstmail@continentalstock.com.

For additional information regarding the reverse stock split, please refer to Biocept’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 16, 2023.

About Biocept

Biocept is a molecular diagnostics company with commercialized assays for patients with carcinomas or melanomas. Our experts have spent years working to change the way physicians look at cerebrospinal fluid (CSF) in cancer patients. Biocept has developed a unique, patented methodology to isolate cancer material that is shed from the primary tumor, such as CSF tumor cells (CSF-TCs) and cell-free DNA (cfDNA). As such, Biocept is a leading commercial provider of testing services designed to enable clinicians to rapidly detect and monitor cancer biomarkers from a cerebrospinal fluid sample.

Investor and Media Contact: Jody Cain, LHA Investor Relations Jcain@lhai.com, 310-691-7100

1 Year Biocept Chart

1 Year Biocept Chart

1 Month Biocept Chart

1 Month Biocept Chart

Your Recent History

Delayed Upgrade Clock